What is Intellia Therapeutics's market cap?

Intellia Therapeutics (NTLA) has a market capitalization of $1.5B and trades on NASDAQ.

What is Intellia Therapeutics's revenue and profitability?

Intellia Therapeutics generated $66.1M in trailing twelve-month revenue with a net loss of $394.6M, representing a net margin of -597.0%, with free cash flow of -$363.6M. These figures are based on the Q1 2026 filing.

Who are Intellia Therapeutics's competitors?

Intellia Therapeutics's key competitors include Editas Medicine, Inc., CRISPR Therapeutics AG, Beam Therapeutics Inc., and others. These companies compete in similar markets and product categories.

Who does Intellia Therapeutics partner with?

Intellia Therapeutics's notable partners include Regeneron Pharmaceuticals, Inc., Kyverna Therapeutics, Inc., AvenCell Therapeutics, Inc., and others.

What subsidiaries does Intellia Therapeutics have?

Intellia Therapeutics's subsidiaries include Rewrite Therapeutics Inc..

Where is Intellia Therapeutics headquartered?

Intellia Therapeutics is headquartered in United States of America and employs approximately 598 people. It has been publicly traded since 2016.

Intellia Therapeutics

NTLA

Intellia Therapeutics is a clinical-stage biopharmaceutical company focused on developing curative treatments using CRISPR-based gene editing technologies.

Market cap

$1.49B+16.7%

Revenue$66.1M+45.0%

Net income-$394.6M+25.0%

Free cash flow-$363.6M+4.6%

EPS (diluted)-$3.53+32.4%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 11, 2026

Revenue$15.0MBeat by $1.2M EPS-$0.81Beat by $0.11

Read the full report

Next report

Aug 6, 2026 (In 1 week)

Revenue estimate$13.0M

EPS estimate-$0.80

Financials

Q1 2026

Income statement

See full

Revenue$15.0M-9.5%

Operating income-$100.5M+16.8%

Net income-$96.2M+15.8%

EPS (diluted)-$0.81+26.4%

Balance sheet

See full

Cash & equivalents$134.7M+6.2%

Total debt$80.5M-32.5%

Total equity$620.9M-20.4%

Total assets$758.8M-23.1%

Cash flow

See full

Operating cash flow-$117.3M+21.2%

CapEx$79.0K-89.3%

Free cash flow-$117.4M+21.5%

Valuation & ratios

Valuation

See full

Market cap$1.49B+16.7%

Enterprise value$1.44B+10.1%

P/S22.6×-3.1×

Profitability

See full

Operating margin-636.6%-202pp

Net margin-597%-194pp

FCF margin-550.2%-140pp

Returns & leverage

See full

Return on equity-56.3%-1.5pp

Debt / equity0.1×0.0×

Current ratio6.1×+1.2×

Competitors

By market cap

ALN

Alnylam Pharmaceuticals$37.2B-12.2%

Ionis Pharmaceuticals$9.2B+41.1%

CRISPR Therapeutics$4.6B-16.4%

Beam Therapeutics$2.6B+23.1%

Intellia Therapeutics$1.5B+9.8%

Prime Medicine$543.7M-1.2%

Editas Medicine$411.3M+66.0%

Precision BioSciences, Inc.$187.1M+231%

By revenue growth

Beam Therapeutics+158%

ALN

Alnylam Pharmaceuticals+82.6%

Intellia Therapeutics+45.0%

Ionis Pharmaceuticals-7.4%

CRISPR Therapeutics-89.1%

By net margin

ALN

Alnylam Pharmaceuticals11.72%+21.5pp

Ionis Pharmaceuticals-64.7%-36.3pp

Intellia Therapeutics-597.04%+557pp

Beam Therapeutics-742.72%+338pp

Prime Medicine-4,342.44%—

CRISPR Therapeutics-13,856.54%-12,833pp

Profile

Intellia Therapeutics is a clinical-stage biopharmaceutical company focused on developing curative treatments using CRISPR-based gene editing technologies. The company leverages proprietary delivery systems, including lipid nanoparticles and oligonucleotides, to address the root causes of severe genetic diseases. Its primary value proposition lies in its ability to perform in vivo genome editing through a single intravenous infusion to achieve lifelong therapeutic benefits.

Competitive position

Intellia is a pioneer in the gene editing space, being the first company to advance in vivo CRISPR candidates into Phase 3 clinical development.

GeographiesUnited States, European Union, United Kingdom

Customer segmentsSpecialty healthcare providers, Rare disease patient populations, Pharmaceutical companies

Business modelR&D intensive, Licensing and Royalties, Collaborative Development

SuppliersThird-party contract manufacturing organizations (CMOs), Academic licensors for foundational CRISPR IP, Specialized raw material suppliers for LNPs and viral vectors

CustomersSpecialized treatment centers, Hospitals, Government and private healthcare payors

CountryUnited States of America

Listed2016

Employees598.0

CEOJohn Leonard

SectorHealthcare

IndustryBiotechnology

Websiteintelliatx.com

FilingsSEC EDGAR

Ask your AI about Intellia Therapeutics.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Intellia Therapeutics's market cap?: Intellia Therapeutics (NTLA) has a market capitalization of $1.5B and trades on NASDAQ.
What is Intellia Therapeutics's revenue and profitability?: Intellia Therapeutics generated $66.1M in trailing twelve-month revenue with a net loss of $394.6M, representing a net margin of -597.0%, with free cash flow of -$363.6M. These figures are based on the Q1 2026 filing.
Who are Intellia Therapeutics's competitors?: Intellia Therapeutics's key competitors include Editas Medicine, Inc., CRISPR Therapeutics AG, Beam Therapeutics Inc., and others. These companies compete in similar markets and product categories.
Who does Intellia Therapeutics partner with?: Intellia Therapeutics's notable partners include Regeneron Pharmaceuticals, Inc., Kyverna Therapeutics, Inc., AvenCell Therapeutics, Inc., and others.
What subsidiaries does Intellia Therapeutics have?: Intellia Therapeutics's subsidiaries include Rewrite Therapeutics Inc..
Where is Intellia Therapeutics headquartered?: Intellia Therapeutics is headquartered in United States of America and employs approximately 598 people. It has been publicly traded since 2016.